News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

April 8, 2014

Completion of Construction for the biopharmaceutical API manufacturing facility in the Takasaki Plant

Tokyo, Japan, April 8, 2014 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo:4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") has completed the construction of the HA4 Plant (biopharmaceutical API manufacturing facility) at the Takasaki Plant in April 8, 2014.

The HA4 Plant has been installed as one of the largest bioreactors for recombinant animal cells (12,000 L bioreactor) in Japan, as well as a purification facility with a large column. By utilizing the manufacturing technology of biopharmaceutical products cultivated by the company, we will realize a larger scale and stable manufacture and continue to make efforts to provide the market with high-quality pharmaceutical products.


<External Appearance of HA4 Plant>


<New plant overview>

Plant Name: HA4 Plant
Scale: Built with reinforced concrete, four-storied, total floor area of approx. 3892 m2
Investment: Approx. 6 billion yen
Purpose: Manufacture of biopharmaceutical API
Schedule: Operations commence will be 1st half, 2016 (January to June)
Characteristics: (1) The facility complies with GMP in Japan, the US, and the EU.
(2) The facility is equipped with a 12,000 L bioreactor, which is one of the largest of its kind in Japan, as well as a large column compatible with this bioreactor.

Contact:

Kyowa Hakko Kirin
Media Contact:
+81-3-3282-1903
or
Investors:
+81-3-3282-0009



To Page Top